# Acromegaly

From Shijiazhuang to the States: CSPC Pharma’s Global Ambitions Get FDA Boost

Chinese pharmaceutical giant CSPC has received US FDA approval to begin clinical trials for its long-acting octreotide injection, a treatment for acromegaly and neuroendocrine tumors. This move highlights the industry's shift toward high-barrier formulations as Chinese firms seek to escape domestic price pressures by expanding into the US market.